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Background: Cancer immunoediting is a dynamic process composed of three phases: elimination (EL), equilibrium
(EQ) and escape (ES) that encompasses the potential host-protective and tumor-sculpting functions of the immune
system throughout tumor development. Animal models are useful tools for studying diseases such as cancer. The
present study was designed to characterize the interaction between mammary adenocarcinoma M-406 and CBi,
CBi− and CBi/L inbred mice lines.
Results: The mammary adenocarcinoma M-406 developed spontaneously in a CBi mouse. CBi/L and CBi− mice were
artificially selected for body conformation from CBi. When CBi mice are s.c. challenged with M-406, tumor growths
exponentially in 100% of animals, while in CBi− the tumor growths briefly and then begins a rejection process in 100%
of the animals. In CBi/L the growth of the tumor shows the three phases: 51.6% in ES, 18.5% in EQ and 29.8% in EL.
Conclusions: The results obtained support the conclusion that the system M-406 plus the inbred mouse lines CBi,
CBi− and CBi/L, is a good murine model to study the process of tumor immunoediting.
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Animal models have been in the past, are still at present,
and almost surely will continue to be in the future, very
useful tools in biomedical investigation [1,2]. In the field
of cancer research it is widely known that both, spontan-
eous and chemically-induced tumors, can develop in rats
and mice [3] as well as in other species [4] and that mu-
tations identified in murine models are often similar to
those observed in human tumor cells [5,6]. Although
in vivo models of pathologic processes are useful only if
they provide information that can be extrapolated to
other species of interest, particularly to humans, and it
is known that no model behaves ideally, it is also true
that they allow not only to replicate but also, in some
cases, to anticipate the genetic architecture of complex
human phenotypes as is the case of cancer disease. While
in vitro models provide a plain system for studying some
of their components in controlled conditions, in vivo* Correspondence: viviana.rozados@gmail.com
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unless otherwise stated.models allow obtaining answers that go beyond the cell or
tissue level since they involve a whole living organism who
can be studied during the evolution of disease. CBi is an
inbred mouse strain derived from an outbred population
generated by crossing BALB/c, Rockland, NIH and Swiss
mice. It was generated to be used as a base population of
broad genetic basis and as the control line of an experi-
ment of artificial body-conformation selection which gave
rise, among others, to CBi− and CBi/L mice lines [7,8].
During selection, the lines were inbred by limiting the
population size [9] until an average theoretical inbreeding
coefficient of approximately 0.985 was reached. From then
on, a regular system of inbreeding involving full-sib (FS)
mating was applied and maintained for more than 30 gen-
erations giving rise to CBi/L FS, CBi− FS and CBi FS lines.
Mice belonging to these FS lines show a heterogeneous be-
havior in their resistance and susceptibility to parasites [10],
in spontaneous mammary carcinogenesis [11] and when
challenged with M-406 mammary adenocarcinoma, a
tumor which arose spontaneously in a female CBi mouse.
While in CBi FS the tumor grows exponentially in 100% of
challenged animals, in CBi− FS the tumor grows briefly and
then begins a rejection process in 100% of the animals. InLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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begins with an exponential growth pattern in all challenged
mice and, after a variable length period, the tumor is com-
pletely eliminated in some individuals while in others
continues growing exponentially or enters in a state of equi-
librium where no additional growth is detectable. After the
equilibrium phase the tumor resumes the exponential
growth becoming lethal in some animals, while in others it
begins a process of rejection until its complete elimination.
The interaction between tumor cells and the immune
system is very complex. It is currently accepted that the im-
mune system can not only protect against tumor develop-
ment but it is also capable of stimulating tumor growth. On
one side, both innate and adaptive immune mechanisms
act in synergism in order to counteract tumor growth
before it becomes clinically apparent. On the other side,
the immune system can also promote tumor progression
through chronic inflammation, immunoselection of poorly
immunogenic variants and by suppressing antitumor im-
munity. These dual host-protective and tumor-promoting
actions of immunity are referred to as cancer immunoedit-
ing [12]. This phenomenon consists of three steps: elimin-
ation, equilibrium and escape, which are known as the
three E´s of tumor immunoediting [12-14]. The present
study was designed to characterize the interaction between
mammary adenocarcinoma M-406 and CBi FS, CBi− FS
and CBi/L FS inbred mice lines, as a model for studying the
process of cancer immunoediting.
Methods
Animals
Ten-weeks-old CBi FS, CBi− FS and CBi/L FS (from here
on CBi, CBi− and CBi/L, respectively) female mice belong-
ing to the Institute of Experimental Genetics, School of
Medical Sciences, National University of Rosario breeding
facilities, were used. All mice were kept in the same room
under the same breeding conditions (23 ± 1°C, on a 12-
hour-on/12-hour-off light cycle) and received the same
diet (Cargill Laboratory Chow, pelletized) and water ad
libitum. Animals were treated in accordance with the in-
stitutional regulations which comply with the guidelines
issued by the Canadian Council on Animal Care [15].
Tumor
According to Squartini’s classification [16] M-406 is a type B
semi-differentiated mammary adenocarcinoma. It is a triple-
negative tumor (ER−, PR−, HER-2−) that arose spontan-
eously in an inbred CBi female mouse and it is maintained
in vivo by serial intraperitoneal passages in syngeneic mice.
Experimental model
All experiments were performed with prior approval from
the Bioethics Committe of the Faculty of Medical Sciences
of the UNR, Argentine, IMED 249, Res N°1383/12.Tumor growth with inoculum by trocar
Female CBi (n = 52), CBi− (n = 52) and CBi/L (n = 150)
mice were s.c. challenged in the lateral flank with M-406
by trocar (three tumor fragments ≈ 8x105 cells) on day 0.
Minor and major tumor diameters were measured with a
caliper three times a week from day 3 on, and tumor vol-
ume was estimated according to the formula [V = (minor
diameter)2 × major diameter × 0.4]. Tumor volume versus
time elapsed since tumor challenge data were adjusted with
an exponential model [Vt = Start.e^(k.t)], where Start is the
value of tumor volume (mm3) at t = 0, Vt is the tumor vol-
ume at t time, t indicates days post tumor inoculation
and k is the exponential growth rate (volume being added
to the system proportional to the volume already
present). Tumor volume doubling time (TvDT) was
calculated as TvDT = ln2/k. Animals were classified as,
Escape (ES): animals in which the tumor grew exponen-
tially, Equilibrium (EQ): animals in which tumor volume
remained constant for at least 10 consecutive days, and
Elimination (EL): animals in which the tumor was com-
pletely eliminated.Evaluation of spontaneous metastasis
When tumors in ES phase (CBi and CBi/L lines) reached
the maximum volume ethically permitted by the Canadian
Council on Animal Care [15], mice were euthanized, their
lungs were excised and fixed in Bouin solution and the
metastatic foci were determined. The lungs are the main
metastatic site of M-406 tumor when growing s.c. in CBi
and CBi/L lines.Tumor growth with counted inoculum
In a subsequent experiment CBi and CBi− mice (n = 5/
group/line) were challenged with M-406 in the lateral
flank according to the following specifications: Group I
with trocar (three tumor fragments ≈ 8×105 cells) and
Groups II, III and IV with suspensions containing 8×105,
4×105 and 2×105 tumor cells for CBi and 8×105, 16×105
and 32×105 tumor cells for CBi−, respectively.
In both experiments, the behavior of tumor bearing ani-
mals was monitored daily and when the tumor reached
the maximum volume allowed by ethical standards, mice
were euthanized by CO2 overexposure.Cell suspensions
Spleens cells: CBi− and CBi/L animals, bearing tumors in
EL phase, were euthanized by CO2 overexposure, their
spleens were excised and cellular suspensions were
obtained by mechanical disruption in RPMI medium.
Tumor cells: tumors from CBi mice bearing i.p. M-406
were excised and cell suspensions were obtained by
mechanical disruption in RPMI medium.
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CBi animals (n = 10/group) were inoculated s.c. in the right
flank with 0.1 ml of different cell suspensions containing:
4105 tumor cells in RPMI medium (Control), 4×105
tumor cells + 7×105 spleen cells from CBi− EL (Group I)
and 4×105 tumor cells + 7×105 spleen cells from CBi/L
EL (Group II). Tumor size was monitored three times a
week until tumor size reached ethical limits (Figure 1).
Conditioned medium
Tumor conditioned medium (CT): tumor cells obtained
from CBi mice bearing i.p. M-406 were cultured in RMPI +
10% FBS for 24 h at 37°C and 5% CO2 (4×10
5 cells/100 μl).
The suspension was centrifuged 10 min at 2000 rpm and
the supernatant was separated and stored at -20°C.
Mononuclear cells (MO) conditioned medium (CMO):
blood was drawn by cardiac puncture with EDTA from
mice belonging to the three lines: Naïve (N): non-
challenged with tumor (CMO-CBi N, CMO-CBi− N and
CMO-CBi/L N) and M-406 bearers (CMO-CBi ES, CMO-
CBi− EL, CMO-CBi/L EL and CMO-CBi/L ES). Mono-
nuclear cells were obtained by Ficoll-Paque PLUS (GE
Healthcare, USA) gradient centrifugation. Then, 4×105
mononuclear cells/100 μl were cultured in RPMI + 10%
FBS for 24 h at 37°C and 5% CO2. The suspension was
centrifuged 10 min at 2000 rpm and the supernatant was
separated and stored at −20°C.
Proliferation assay
Tumor cells: M-406 (5×104 cells) was cultured with dif-
ferent CMO (100 μl) and with RPMI (Control group,
reference value, 100%).
Mononuclear cells: MO (5×104 cells) from naïve CBi
(MO-CBi N), CBi− (MO-CBi− N) and CBi/L (MO-CBi/
L N) mice were cultured with CT (100 μl).Figure 1 Experimental model of Winn assay.Cells were incubated for 24 h, at 37°C and 5% of CO2
and cell proliferation was evaluated with WST-1 kit (Roche,
Argentina) (Figure 2).
Statistical analysis
Statistically significant differences between groups (P values
less than 0.05) were assessed using Mann–Whitney U test
or Kruskal-Wallis one-way analysis of variance by ranks
followed by Dunn's post-test, Student’s t test, Log-rank-
Mantel-Cox test, one way ANOVA followed by Tukey´s
multiple comparison test and Spearman correlation, as ap-
propriate (GraphPad, version 3.0).
Results
Tumor growth with inoculum by trocar
Irrespective of the mouse line, M-406 grew in all chal-
lenged animals. In CBi mice (Figure 3a) the tumor
maintained an exponentially growing pattern (escape
phase, ES) until it reached the maximum volume
allowed according to ethical guidelines. On the contrary,
after a short period of initial growth all CBi− mice rejected
the tumor (elimination phase, EL) (Figure 3b). In CBi/L
the tumor displayed the three phases of cancer immu-
noediting as it was eliminated (EL) in 30.0% of chal-
lenged mice, reached an equilibrium phase (EQ) in
18.7% and maintained a continuous growing pattern
(ES) in the remainder 51.3% (Figure 3e,c and d, re-
spectively) (Table 1).
Escape phase: it was only observed in CBi and CBi/L
mice. In CBi mice, TvDT (median; range) [4.00 (2.78-
5.08)] was lower (P = 0.0014) than that of CBi/L animals,
[4.94 (3.04-7.40)] (Figure 4a). These differences were mir-
rored in the survival behavior as median survival times of
28 and 42 days were observed in CBi and CBi/L mice, re-
spectively (P < 0.0001) (Figure 4b).
Figure 2 Experimental model of proliferation assay.
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reached before the beginning of rejection was signifi-
cantly higher (P = 0.023) in CBi− mice (mean ± SEM:
42.5 ± 7.73 mm3) than in CBi/L mice (18.7 ± 2.86 mm3)
(Figure 4c). However, tumor-bearing time was signifi-
cantly lower (P = 0.0019) in CBi− mice (days: median;
range) [19 (14–40)] than in CBi/L mice [26 (9–49)], in-
dicating that the actual elimination of the tumor is fas-
ter in CBi− than in CBi/L (Figure 4d).Figure 3 Evolution of M-406 tumor growth with inoculum by trocar i
d) CBi/L (EQ); e) CBi/L (EL). Escape curves were fitted to an exponential groEquilibrium phase: it was only observed in CBi/L animals
which tumor volumes were stable over a period of at least
10 days. The average tumor volume was 37.6 ± 14.70 mm3.
In all mice lines the presence of tumor was studied by
classic H&E techniques (data not shown).
Evaluation of spontaneous metastasis
The number of animals with lung metastases foci was
lower in CBi line [17% (9/52)] than in CBi/L [58% (29/50)]n the three lines of mice. a) CBi (ES); b) CBi− (EL); c) CBi/L (ES);
wth equation.
Table 1 Animals in escape, equilibrium and elimination
phases
CBi CBi− CBi/L
Take 100% 100% 100%
(52/52) (52/52) (150/150)
Escape 100% - 51,3%
(52/52) (77/150)
Equilibrium - - 18,7%
(28/150)
Elimination - 100% 30,0%
(52/52) (45/150)
Figure 4 Escape and elimination phases in CBi, CBi− and CBi/L mice. a
Whitney test); b) Survival curves of CBi and CBi/L mice in ES phase (P < 0.000
(P = 0.0023, Student’s t test); d) Days of tumor bearing: CBi− vs CBi/L (P = 0.001
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out and with metastases is shown in Figures 5b and c,
respectively.Tumor growth with counted inoculum
M-406 grew in all CBi mice groups (ES) until it reached the
maximum ethically allowed volume (Figure 6a). At day 30
post-challenge, tumor volume showed the following de-
creasing pattern (GI >GII > GIII > GIV) compatible with
the growing size of the inoculum although no significant
differences among groups were evident either on TvDT
(Figure 6b) or in Start values (START) (Figure 6c).
In CBi− mice the four groups showed 100% of tumor
takes and 100% of tumor regression (Figure 6d). Tumor
bearing time tend to be longer in GIV (47 days) in com-
parison to GI (28), GII (30) and GIII [16], without reach-
ing statistical significance (Figure 6e).) Tumor volume doubling time (TvDT); CBi vs CBi/L (P = 0.0014, Mann
1, Log-rank test Mantel-Cox); c) Maximun tumor volume: CBi− vs CBi/L
9, Mann Whitney test).
Figure 5 Lung metastasis development in CBi (n = 52) and CBi/L (n = 50) mice. a) Percentage of mice developing metastasis. CBi vs CBi/L
(P = 0.0001, Fisher's Exact Test); b) Lung without metastasis; c) Lung with metastasis.
Figure 6 Evolution of M-406 tumor growth with counted inoculum in CBi and CBi− mice. Group I: tumor challenge with trocar and Groups
II, III and IV, inoculated with tumor cells suspension: 8x105, 16x105 and 32x105 cells, respectively. a) Tumor volume in CBi mice; b) TvDT in CBi
mice; c) Start value in CBi mice; d) Tumor volume in CBi− mice, e) Days of tumor bearing in CBi− mice.
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Figure 7 Winn assay. Control: 4x105 tumor cells in RPMI medium; Group I: 4x105 tumor cells + 7x105 spleen cells from CBi− EL; Group II: 4x105
tumor cells + 7x105 spleen cells from CBi/L EL. a) Curves were fitted to an exponential growth equation (P < 0,0001); b) Survival proportions
(P = 0.001, Log-rank Mantel-Cox test); c) TvDT (N.S. Kruskal-Wallis test); d) Latency time (P = 0.002, Kruskal-Wallis test).
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The exponential growth pattern of tumor volumes differed
among groups (P < 0.0001) (Figure 7a). The co-inoculation
of tumor cells plus spleen cells from both CBi− and CBi/L
in elimination phase (Groups I and II, respectively) had a
negative effect on tumor growth. As a consequence, sur-
vival curves also showed significant differences. The con-
trol group showed a median survival time of 28 days,
whereas groups I and II had a significantly higher median
survival time: 33.5 days and 37 days, respectively (P = 0.001)
(Figure 7b). Although there were no significant differences
in TvDT among groups (P > 0.05) (Figure 7c), tumor
latency, defined as the time elapsed from the inoculation of
the tumor cells until the tumor became palpable, was
significantly lower in animals of the Control group (days:
median; range [3 [3-8]]) and Group I [3 [3-12]] than those
of Group II [12 [3-21]] (P = 0.002) (Figure 7d).Effect of mononuclear cells’ conditioned media on
tumor proliferation
The incubation of M-406 cells with CMO-CBi N in-
creased the proliferation with respect to Control group(P = 0.0073). No differences were observed among the
other groups (CMO-CBi N and Control vs CMO-CBi
ES) (Figure 8a). No differences with Control group were
observed in M-406 cells proliferation when incubated
with CMO-CBi− N or CMO-CBi− EL (Figure 8b). On
the contrary, when tumor cells were incubated with
CMO-CBi/L N the proliferation was significantly higher
than that obtained with cells incubated with RPMI (Con-
trol) or CMO-CBi/L EL (P = 0.0084) (Figure 8c).
Effect of tumor conditioned media (CT) on mononuclear
cells’ proliferation
When proliferation of mononuclear cells from Naïve CBi,
CBi− or CBi/L mice incubated with CT was evaluated,
MO-CBi− N proliferation was higher than MO-CBi N and
MO-CBi/L N (P = 0.0073) (Figure 9).
Discussion
In the last fifteen years, the interest in cancer immunosur-
veillance has re-emerged. Shankaran et al. have shown
that, besides its protective role against disease, the im-
mune system may also promote the emergence of primary
tumors with reduced immunogenicity that are capable of
Figure 8 Percentage of proliferation of M-406 cells incubated with mononuclear cells conditioned medium (n = 4): a) CBi: Naïve vs Control,
P = 0.0073; b) CBi−, N.S.; c) CBi/L: Naïve vs Control and vs EL, P = 0.0084; (Kruskal-Wallis test and Dunn´s multiple comparisons test).
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findings prompted the development of the cancer immu-
noediting hypothesis to encompass more broadly the po-
tential host-protective and tumor-sculpting functions of
the immune system throughout tumor development [14].
Cancer immunoediting which is known as the three E’sFigure 9 Percentage of proliferation of mononuclear cells from
Naïve mice incubated with conditioned media from M-406
tumor cells (CT). MO-CBi− N vs MO-CBi N and vs MO-CBi/L N
P = 0.0073 (Kruskal-Wallis test).theory, is a dynamic process composed of three phases:
ES, EQ and EL. The Elimination phase corresponds to the
original concept of cancer immunosurveillance whereby
cancer cells are successfully recognized and destroyed by
the immune system. If tumor cells are not completely
eliminated they may proceed into an Equilibruim phase
in which the immune system is able to control tumor
growth but is incapable to eliminate it completely. Over
the time, however, cancer may overcome the entire im-
mune response and enter into the third phase, or Escape
phase, during which it progresses and metastasizes [17].
The inbred mouse lines CBi, CBi− and CBi/L of the Insti-
tute of Experimental Genetics, School of Medical Sciences,
UNR, jointly with M-406 mammary adenocarcinoma, pro-
vide a suitable model for studying the three “E’s” of tumor
immunoediting. Direct and correlated responses to selective
pressure together with the non-directional effects of in-
breeding and genetic drift suggest that these lines have
fixed different allelic combinations, which would explain
the uniform behavior observed within lines as well as the
differences observed between them. While CBi behaves as
a susceptible line in terms of mammary adenocarcinoma
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iors -susceptibility or resistance- proved to be independent
of the integrity and the size (number of cells) of the inocu-
lum used. On one hand the results showed that inoculum
size was only related to tumor bearing time. On the other
hand, despite having quadrupled the number of tumor
cells used to challenge animals with trocar, CBi− mice
were able to inhibit M-406 growth, thus confirming the
status of line resistant to the challenge with this particular
type of tumor. In contrast, CBi mice, independently of the
number of tumor cells inoculated, even when that number
was four times lower, were unable to halt M-406 growth, a
fact that supports the status of susceptible line. The het-
erogeneous behavior observed in CBi/L could be ex-
plained if the relationship between M-406 and the
immune system was modeled as a threshold character.
Undoubtedly, from a genetic point of view, the immune
response against a tumor is a quantitative trait as it in-
volves many genes. According to the proposed threshold
model, the immune response against tumor challenge is
inherited as a continuous trait with a threshold which im-
poses a discontinuity on the phenotypic expression (resist-
ance or susceptibility) of the character. Several loci in
mouse, like Mmtg1, Mmtg2, Mmtg3, Mtes1, Apmt1,
Apmt2 were involved in cancer-susceptibility [18]. Also,
three QTLS that control tumor incidence and/or latency
were mapped in the crosses between BALB/c mice (pre-
disposed to develop spontaneous mammary tumors, espe-
cially when carrying a single normal Tp53 allele) and
C57BL/6 mice (which are resistant to mammary cancer).
In the aforementioned model, Dmbt1 is a solid candidate
for a putative tumor suppressor gene involved in im-
mune defense [19,20]. The genetic architecture of the trait,
determines, i.e., that the allelic frequencies of those genes
involved in the immune response corresponding to CBi−
and CBi mice, clearly lie above and below, respectively, of
the threshold, thus expressing in each case, the resistance
or susceptibility phenotypes. In contrast, gene arrangement
in CBi/L localized this particular line in the boundaries of
the threshold allowing the emergence of the different pat-
terns associated with the three E’s theory [12,14].
Tumor doubling time values and survival curves indi-
cate that the EL and ES phases differ in CBi/L line from
those observed in CBi and CBi− mice. Interestingly, both
processes lasted more in CBi/L than in CBi and CBi−. In
the ES phase, tumor-growth rate was slower in CBi/L than
in CBi, a fact evident when tumor doubling times and sur-
vival curves were compared. At the same time, the elimin-
ation process was slower in CBi/L than in CBi−. The
interaction between tumor cells and the immune response
in CBi/L would be weaker than that generated in CBi−
line, but would still be effective in some cases for a
complete tumor rejection. These patterns also agree with
the observation that M-406 reached the maximum volumein CBi/L later than in CBi mice. The usefulness of the ex-
ponential model to characterize tumor growth from a
quantitative point of view, allows using it as a tool for
prognostic purposes and for measuring the therapeutic ef-
fects of different treatment modalities [21,22].
The development of metastasis is an important hurdle
for cancer treatment. Interestingly, CBi/L mice showed
more lung metastasis than CBi mice. The capacity to
metastasize is due to factors both extrinsic and intrinsic
to the tumor cells [23]. The differences observed in the de-
velopment of metastasis between CBi and CBi/L could be
associated with extrinsic factors like host susceptibility,
immune response, neo-angiogenesis and the peritumoral
stroma. Hence, in order to understand the aforementioned
differences, these and other potentially involved factors
should be studied. For example, having in mind the role of
the intrinsic factors, it could be hypothesized that the
probability of metastasis development would be higher in
CBi/L than in CBi mice, because of the longer time
needed by the tumor to reach the maximum allowed vol-
ume in CBi/L due to the special interaction between the
tumor cells and the immune response of each host.
Evidence derived from the Winn assay indicated that
spleen cells from immunized animals were able to inhibit
tumor growth, at least temporarily. Differences in tumor
growth rate and survival curves were evident when mice
were challenged jointly with tumor cells and spleen cells
derived from immunized animals. When tumor growth
was studied in CBi animals challenged with M-406 cells
plus spleen cells from CBi− or CBi/L tumor-bearing mice
in EL phase, different responses were observed in latency
time. Although the tumor grew exponentially in all ani-
mals, the increase in latency time was evident in mice
challenged with tumor cells plus CBi/L spleen cells in EL
(Group II) with respect to the Control group that showed
the lowest values. The response in Group I was intermedi-
ate between that of Control and Group II. These results
do not agree with previous ones showing that the process
of EL lasted more in CBi/L than in CBi− mice (Figure 2d);
so, it could be expected that MO from CBi/L would be
less able to delay the beginning of tumor growth than MO
from CBi− mice. Such a discrepancy deserves further stud-
ies to unveil its biologic base.
In order to deepen the knowledge of CBi/M-406 model,
the tumor cell growth in different CMO from naive and
tumor bearing animals in the different tumor-growth
phases was evaluated. The higher proliferation of M-406
cells observed when cultured with CMO from both Naïve
CBi/L and CBi mice indicates that these media would con-
tain factor/s like IL-2, IL-4, INF-γ, IL-10, TNF-α and many
others, yet to be identified, capable to stimulate or inhibit
tumor growth. This observation agrees with the results
obtained by Franca [24] who found that direct contact be-
tween fresh human mononuclear cells and conditioned
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and VEGF, factors which are clearly involved in tumor
growth.
Conclusions
The results herein described, taken together, suggest that
these different inbred lines of mice plus the M-406 mam-
mary adenocarcinoma perform as a very good model for
studying the process of tumor immunoediting. Particularly,
the present studies indicate that CBi/L mice, despite
having a high coefficient of inbreeding, can develop any
of the three phases of tumor immunoediting after being
challenged with M-406 mammary adenocarcinoma, un-
like CBi− or CBi mice, which present a homogeneous
behavior. The recognition of the mechanisms involved in
the different phases of tumor growth, would likely lead
to design different strategies for breast cancer treatment
or prevention.
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